Non-small cell lung cancer (NSCLC) is a serious threat to the health of older adults. Despite
the significant progress in immunotherapy, effective treatments for NSCLC remain limited …

Introduction This integrated analysis of a phase 1/2 study (NCT03046992) assessed the
efficacy and safety of lazertinib, a third-generation epidermal growth factor receptor (EGFR) …

Background Osimertinib is a recently approved third-generation epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

To date, driver genes for pancreatic cancer treatment are difficult to pursue therapeutically.
Targeting mutated KRAS, the most renowned driver gene in pancreatic cancer, is an active …

Introduction Patients with EGFR-mutant NSCLC experience variable duration of benefit on
EGFR tyrosine kinase inhibitors. The effect of concurrent genomic alterations on outcome …

The standard diagnostics procedure for non-small-cell lung cancer (NSCLC) requires a
pathological evaluation of tissue samples obtained by surgery or biopsy, which are …

Mercaptopurine (MCP) is an anticancer drug that is used to treat acute lymphoblastic
leukemia. The therapeutic effect of the mercaptopurine limits its severe side effects like other …

Family with sequence similarity 83, member A (FAM83A) plays an essential and
fundamental role in the proliferation, progression, and apoptosis of many malignant tumors …

Lung cancer is a leading cause of cancer-related deaths in Latin America, with non-small
cell lung cancer (NSCLC) being the most prevalent. The current study aimed to report real …

Simple Summary Osimertinib is a third-generation epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in …